Organisation paid for research Program year 2025 Source: CMS Open Payments

HCP Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$738,947

78 payments

Through program year 2025, HCP Clinical Research LLC is reported as receiving $738,947 in research payments, across 78 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $81,286 3
2024 Research $71,304 4
2023 Research $158,629 6
2022 Research $79,287 4
2021 Research $47,449 4
2020 Research $15,625 3
2019 Research $285,366 54

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $425,508 23 payments
  2. AbbVie, Inc. $135,786 28 payments
  3. Amgen Inc. $98,357 5 payments
  4. Novo Nordisk AS $24,368 12 payments
  5. Pfizer Inc. $18,423 2 payments
  6. Novartis Pharmaceuticals Corporation $12,663 1 payment
  7. Ucb SA $10,618 1 payment
  8. Boston Scientific Corporation $7,262 4 payments
  9. Celgene Corporation $3,944 1 payment
  10. Regeneron Pharmaceuticals, Inc. $2,019 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $130,487 4 payments
  2. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $106,740 2 payments
  3. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $76,902 4 payments
  4. M12-817 $61,142 13 payments
  5. Gould $51,945 1 payment
  6. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized Double-Blind Placebo-Controlled Trial (Surmount-4) $43,864 2 payments
  7. M16-283 $40,565 5 payments
  8. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus $33,367 2 payments
  9. (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States $31,858 3 payments
  10. M14-702 $28,079 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record